Axsome Therapeutics, Inc.
AXSM
$224.03
$7.563.49%
NASDAQ
| 03/31/2026 | 12/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -2.45% | 14.62% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -2.45% | 14.62% | |||
| Cost of Revenue | 19.43% | 3.50% | |||
| Gross Profit | -3.92% | 15.46% | |||
| SG&A Expenses | 9.27% | 12.69% | |||
| Depreciation & Amortization | -2.18% | 0.00% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 9.46% | 13.78% | |||
| Operating Income | -74.23% | -9.42% | |||
| Income Before Tax | -129.45% | 40.44% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -126.00% | 39.53% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -126.00% | 39.53% | |||
| EBIT | -74.23% | -9.42% | |||
| EBITDA | -88.06% | -2.95% | |||
| EPS Basic | -123.47% | 40.26% | |||
| Normalized Basic EPS | -70.01% | -7.95% | |||
| EPS Diluted | -123.47% | 40.26% | |||
| Normalized Diluted EPS | -70.01% | -7.95% | |||
| Average Basic Shares Outstanding | 1.12% | 1.22% | |||
| Average Diluted Shares Outstanding | 1.12% | 1.22% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||